| |
| |
|
| Insider
Information: |
Tessier-Lavigne Marc |
| Relationship: |
Director |
| City: |
So San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
2,228,119 |
|
|
Indirect Shares
|
236,869 |
|
|
| Direct
Value |
$34,257,770 |
|
|
|
Indirect Value
|
$3,654,889 |
|
|
| Total
Shares |
2,464,988 |
|
|
| Total
Value |
$37,912,658 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 42.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pfizer Inc |
PFE |
Director |
2011-12-12 |
104 |
|
0 |
Premium* |
|
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2023-01-03 |
2,434 |
2013-05-06 |
0 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2013-07-24 |
101,009 |
|
0 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
Director |
2014-12-23 |
250,000 |
|
0 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
Director |
2023-06-01 |
1,874,572 |
2023-06-01 |
236,869 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,216 |
1,874,572 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
2,434 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-11-23 |
4 |
AS |
$30.48 |
$609,600 |
D/D |
(20,000) |
1,870,356 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-11-02 |
4 |
AS |
$30.33 |
$341,273 |
D/D |
(11,252) |
1,890,356 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-11-01 |
4 |
AS |
$30.20 |
$264,190 |
D/D |
(8,748) |
1,901,608 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-10-03 |
4 |
AS |
$718.00 |
$2,593,416 |
D/D |
(3,612) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-10-03 |
4 |
OE |
$413.33 |
$1,492,948 |
D/D |
3,612 |
5,881 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-09-30 |
4 |
OE |
$413.33 |
$1,416,895 |
D/D |
3,428 |
5,697 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-09-30 |
4 |
AS |
$698.00 |
$2,392,744 |
D/D |
(3,428) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-09-29 |
4 |
AS |
$686.89 |
$2,624,684 |
D/D |
(3,798) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-09-29 |
4 |
OE |
$413.33 |
$1,569,827 |
D/D |
3,798 |
6,067 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-09-28 |
4 |
AS |
$30.74 |
$616,304 |
D/D |
(20,000) |
1,910,356 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-08-23 |
4 |
AS |
$31.61 |
$632,282 |
D/D |
(20,000) |
1,930,356 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-07-25 |
4 |
S |
$35.60 |
$712,110 |
D/D |
(20,000) |
1,950,356 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-24 |
4 |
D |
$30.53 |
$1,430,968 |
D/D |
(46,750) |
1,970,356 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-23 |
4 |
D |
$31.10 |
$412,076 |
D/D |
(13,250) |
2,017,106 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
2,030,356 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-03-23 |
4 |
S |
$33.40 |
$676,583 |
D/D |
(20,000) |
2,024,370 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-21 |
4 |
AS |
$690.00 |
$5,132,910 |
D/D |
(7,439) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-21 |
4 |
OE |
$380.95 |
$2,833,887 |
D/D |
7,439 |
9,708 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-17 |
4 |
AS |
$680.00 |
$5,324,400 |
D/D |
(7,830) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-17 |
4 |
OE |
$376.69 |
$2,949,483 |
D/D |
7,830 |
10,099 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-16 |
4 |
AS |
$675.00 |
$2,943,675 |
D/D |
(4,361) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-16 |
4 |
OE |
$374.12 |
$1,631,537 |
D/D |
4,361 |
6,630 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
2,269 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
